** Ajanta Pharma AJPH.NS rises 2.5% to 2,757.30 rupees
** Motilal Oswal says AJPH's partnership with Biocon BION.NS to source weight-loss drug semaglutide is "meaningful step" towards introducing newer therapies, way for AJPH to secure market share
** Forecasts potential annualised sales from semaglutide in Asia and Africa at $25-30 mln from H2 FY28, EBITDA margin of 50-55%
** Expects AJPH's overall revenue and profit to grow at 11% and 16% CAGR, respectively, over FY26-28
** Reiterates "buy" rating on AJPH with PT of 3,145 rupees
** Avg rating of 13 analysts is "buy"; median PT is 3,120 rupees - data compiled by LSEG
** YTD, AJPH down 6% vs pharma index's .NIPHARM 3.9% decline
(Reporting by Kashish Tandon in Bengaluru)
((Kashish.tandon@thomsonreuters.com))